Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05936970 · ClinicalTrials.gov registry record

Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD

A clinical trial of Rheumatoid Arthritis, sponsored by Aqtual.

Recruiting
Registry status
1,410
Enrollment target
1
Study location

NCT05936970 is a study of Rheumatoid Arthritis that is actively recruiting participants, run by Aqtual. The registered enrollment target is 1,410 participants, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05936970, a study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Aqtual.

RECRUITING
Registry status
1,410 participants
Enrollment target
1
Study location

Study Summary

The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.

Conditions Studied

Study Locations (1)

North Carolina

  • Arthritis and Osteoporosis Consultants of the Carolinas - Charlotte

Trial Details

FieldValue
Enrollment Target 1,410 participants
Start Date 2023-06-29
Est. Completion 2025-12

Sponsor

Aqtual

1 total trials

What the Registry Record Tells You About NCT05936970

The ClinicalTrials.gov registry entry for NCT05936970 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,410 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (70% lower). The listed sponsor is Aqtual, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT05936970 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05936970 about?

NCT05936970 is a clinical study titled "Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD". The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.

What is the current status of trial NCT05936970?

This trial is currently recruiting. The enrollment target is 1,410 participants. The study started on 2023-06-29. Estimated completion is 2025-12.

What conditions does trial NCT05936970 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

Who is sponsoring clinical trial NCT05936970?

This trial is sponsored by Aqtual, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05936970 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.